Chan M, Lee-Pack L R, Favell K, Chan C K
Department of Medicine, Toronto Hospital, University of Toronto, Ontario, Canada.
J Aerosol Med. 1996 Winter;9(4):521-6. doi: 10.1089/jam.1996.9.521.
We conducted a prospective, unblinded, nonrandomized, multiple crossover study to assess the acute pulmonary effects of a new jet nebulizer-Parineb, comparing it to Respirgard II (jet nebulizer) and Fisoneb (ultrasonic nebulizer) for administering aerosol pentamidine (AP). Twenty-three HIV patients received AP at 60 mg dissolved in 3 ml sterile water with Parineb and Fisoneb and 300 mg dissolved in 5 ml sterile water with Respirgard II on three successive clinic visits. Twelve patients known to develop bronchospasm with AP received 200 micrograms of salbutamol as premedication for all three nebulizers. Eleven subjects received AP without bronchodilator premedication. All subjects had a reduction in flow rates with AP. No significant difference was noted in the reduction of flow rates between the three nebulizers in those patients without prior history of bronchospasm with AP. However, there was a significantly greater reduction in flow rates with Parineb in patients with known AP-induced bronchospasm despite premedication with bronchodilator. This decrease in flow rates with Parineb was not felt by patients based on the subjective rating of cough using a visual analog score when compared to the other two nebulizers. Parineb should be used cautiously in individuals with known AP-induced bronchospasm.
我们进行了一项前瞻性、非盲法、非随机、多次交叉研究，以评估新型喷射雾化器Parineb的急性肺部效应，将其与Respirgard II（喷射雾化器）和Fisoneb（超声雾化器）用于雾化戊烷脒（AP）时进行比较。23名HIV患者在三次连续的门诊就诊中，分别使用Parineb和Fisoneb将60毫克AP溶解于3毫升无菌水中，以及使用Respirgard II将300毫克AP溶解于5毫升无菌水中进行治疗。12名已知使用AP会发生支气管痉挛的患者，在使用这三种雾化器时均预先服用200微克沙丁胺醇。11名受试者在未预先使用支气管扩张剂的情况下接受AP治疗。所有受试者使用AP后流速均降低。在那些既往无AP诱发支气管痉挛病史的患者中，三种雾化器在流速降低方面未观察到显著差异。然而，在已知有AP诱发支气管痉挛的患者中，尽管预先使用了支气管扩张剂，但使用Parineb时流速降低更为显著。与其他两种雾化器相比，根据视觉模拟评分法对咳嗽进行主观评估时，患者并未感觉到使用Parineb时流速的降低。对于已知有AP诱发支气管痉挛的个体，应谨慎使用Parineb。
